February 25, 2026 a 12:38 pm
EW: Analysts Ratings - Edwards Lifesciences Corporation
Edwards Lifesciences Corporation maintains a solid position in the medical devices sector, focusing on cutting-edge solutions for heart valve disease and critical care monitoring. Despite facing some volatility, the current analyst sentiment remains robust, with a strong lean towards "Buy" ratings. The company's innovative product lineup and its strategic global reach underpin a generally positive outlook for its stock.
Historical Stock Grades
The recent analyst ratings for Edwards Lifesciences Corporation as of February 2026 show a positive inclination with a total of 33 ratings. Out of these, 5 are Strong Buys and 16 are Buys, reflecting a strong confidence among analysts. The Hold ratings stand at 12, with no Sell or Strong Sell ratings, highlighting a generally optimistic view.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 16 | |
| Hold | 12 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment towards Edwards Lifesciences has remained mostly positive, with a noted increase in Buy recommendations. Over the past months, the total number of ratings has held steady, with a slight shift from Hold to Buy recommendations. Noteworthy trends include:
- Consistent Buy recommendations, indicating confidence in the company's growth potential.
- A decrease in Hold ratings, showing a shift in sentiment towards a more optimistic view on stock performance.
Percentage Trends
The shift in analyst recommendations highlights increasing confidence in Edwards Lifesciences. Over the past year, the share of Buy ratings has increased while Hold ratings have decreased, pointing towards greater confidence in future performance of the stock:
- Strong Buy and Buy ratings together currently make up approximately 63.6% of all recommendations.
- Hold ratings have reduced from previous levels, now representing approximately 36.4%.
- No Sell or Strong Sell ratings in recent months underline strong market sentiment.
Latest Analyst Recommendations
Recent analyst actions maintain a steady outlook, with most recommendations affirming the current rating:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-11 | Hold | Hold | Truist Securities |
| 2026-02-11 | Buy | Buy | Goldman Sachs |
| 2026-02-11 | Overweight | Overweight | Wells Fargo |
| 2026-02-11 | Overweight | Overweight | Piper Sandler |
| 2026-02-11 | Buy | Buy | BTIG |
Analyst Recommendations with Change of Opinion
Several analysts have recently revised their ratings, reflecting a favorable outlook towards Edwards Lifesciences Corporation:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-09 | Buy | Hold | TD Cowen |
| 2025-12-18 | Overweight | Neutral | JP Morgan |
| 2025-10-29 | Peer Perform | Underperform | Wolfe Research |
| 2025-10-29 | Buy | Hold | Jefferies |
| 2025-10-08 | Perform | Outperform | Oppenheimer |
Interpretation
Analyst sentiment overall suggests stability and confidence in Edwards Lifesciences' market performance. The upward trend in Buy recommendations alongside reduced Hold suggests increased optimism. While recent changes signal an evolving viewpoint that favors strategic growth, the absence of negative ratings indicates a stable perception among analysts.
Conclusion
Edwards Lifesciences Corporation maintains a favorable outlook in the analyst community. The combination of consistent Buy ratings and the lack of any negative outlooks underscores its robust position in the medical device industry. As the sentiment tilts more consistently towards positive recommendations, investors may find strengthened possibilities for growth, albeit with recognized market and sector-specific risks. Overall, the company is poised for steady performance, supported by ongoing innovation and strategic positioning.